<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">20150372</PMID>
<DateCompleted>
<Year>2010</Year>
<Month>05</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1523-5866</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>12</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2010</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Neuro-oncology</Title>
<ISOAbbreviation>Neuro-oncology</ISOAbbreviation>
</Journal>
<ArticleTitle>A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.</ArticleTitle>
<Pagination>
<MedlinePgn>95-103</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/neuonc/nop015</ELocationID>
<Abstract>
<AbstractText>Patients with (a) recurrent malignant glioma (MG): glioblastoma (GBM) or recurrent anaplastic glioma (AG), and (b) nonprogressive (NP) GBM following radiation therapy (RT) were eligible. Primary objective for recurrent MG was progression-free survival at 6 months (PFS-6) and overall survival at 12 months for NP GBM post-RT. Secondary objectives for recurrent MGs were response, survival, assessment of toxicity, and pharmacokinetics (PKs). Treatment with enzyme-inducing antiepileptic drugs was not allowed. Patients received 150 mg/day erlotinib. Patients requiring surgery were treated 7 days prior to tumor removal for PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR) and intracellular signaling pathways. Ninety-six patients were evaluable (53 recurrent MG and 43 NP GBM); 5 patients were not evaluable for response. PFS-6 in recurrent GBM was 3% with a median PFS of 2 months; PFS-6 in recurrent AG was 27% with a median PFS of 2 months. Twelve-month survival was 57% in NP GBMs post-RT. Primary toxicity was dermatologic. The tissue-to-plasma ratio normalized to nanograms per gram dry weight for erlotinib and OSI-420 ranged from 25% to 44% and 30% to 59%, respectively, for pretreated surgical patients. No effect on EGFR or intratumoral signaling was seen. Patients with NP GBM post-RT who developed rash in cycle 1 had improved survival (P &lt; .001). Single-agent activity of erlotinib is minimal for recurrent MGs and marginally beneficial following RT for NP GBM patients. Development of rash in cycle 1 correlates with survival in patients with NP GBM after RT.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Raizer</LastName>
<ForeName>Jeffrey J</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. jraizer@nmff.org</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Abrey</LastName>
<ForeName>Lauren E</ForeName>
<Initials>LE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lassman</LastName>
<ForeName>Andrew B</ForeName>
<Initials>AB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chang</LastName>
<ForeName>Susan M</ForeName>
<Initials>SM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lamborn</LastName>
<ForeName>Kathleen R</ForeName>
<Initials>KR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kuhn</LastName>
<ForeName>John G</ForeName>
<Initials>JG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yung</LastName>
<ForeName>W K Alfred</ForeName>
<Initials>WK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gilbert</LastName>
<ForeName>Mark R</ForeName>
<Initials>MR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Aldape</LastName>
<ForeName>Kenneth A</ForeName>
<Initials>KA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wen</LastName>
<ForeName>Patrick Y</ForeName>
<Initials>PY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fine</LastName>
<ForeName>Howard A</ForeName>
<Initials>HA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mehta</LastName>
<ForeName>Minesh</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Deangelis</LastName>
<ForeName>Lisa M</ForeName>
<Initials>LM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lieberman</LastName>
<ForeName>Frank</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cloughesy</LastName>
<ForeName>Timothy F</ForeName>
<Initials>TF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Robins</LastName>
<ForeName>H Ian</ForeName>
<Initials>HI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dancey</LastName>
<ForeName>Janet</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Prados</LastName>
<ForeName>Michael D</ForeName>
<Initials>MD</Initials>
</Author>
<Author ValidYN="Y">
<CollectiveName>North American Brain Tumor Consortium</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>UL1 TR000005</GrantID>
<Acronym>TR</Acronym>
<Agency>NCATS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>M01-RR0865</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 CA62399</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>M01 RR003186</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>M01-RR00079</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01CA62407-08</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA16672</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>5-U01CA62399-09</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>M01-RR00056</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>M01 RR003186-190379</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01CA62421-08</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA62426</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA62422</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01CA62405</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA62399</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA62412</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2009</Year>
<Month>12</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Neuro Oncol</MedlineTA>
<NlmUniqueID>100887420</NlmUniqueID>
<ISSNLinking>1522-8517</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>DA87705X9K</RegistryNumber>
<NameOfSubstance UI="D000069347">Erlotinib Hydrochloride</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000069347">Erlotinib Hydrochloride</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005909">Glioblastoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005910">Glioma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009364">Neoplasm Recurrence, Local</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011799">Quinazolines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014018">Tissue Distribution</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2010</Year>
<Month>2</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2010</Year>
<Month>2</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2010</Year>
<Month>5</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">20150372</ArticleId>
<ArticleId IdType="pii">nop015</ArticleId>
<ArticleId IdType="doi">10.1093/neuonc/nop015</ArticleId>
<ArticleId IdType="pmc">PMC2940554</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>N Engl J Med. 2005 Mar 10;352(10):1036-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15758016</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2005 Mar 10;352(10):987-96</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15758009</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Neurology. 2005 Apr 26;64(8):1444-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15851741</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):318-27</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15890570</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Natl Cancer Inst. 2005 Jun 15;97(12):880-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15956649</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2005 Nov 1;11(21):7841-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16278407</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2005 Nov 10;353(19):2012-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16282176</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lung Cancer. 2006 Jan;51(1):89-96</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16290256</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Neuro Oncol. 2006 Jan;8(1):67-78</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16443950</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1192-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16626884</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2006 Dec 15;12(24):7232-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17189394</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):378-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17255257</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neurooncol. 2007 Apr;82(2):175-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17008949</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Cancer. 2007 Apr 10;96(7):1047-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17353924</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS Med. 2006 Dec;3(12):e485</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17177598</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2007 Oct 12;318(5848):287-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17872411</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Chemother Pharmacol. 2008 Aug;62(3):387-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17932674</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neurooncol. 2008 Sep;89(2):211-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18458820</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2008 Aug 7;27(34):4702-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18408761</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2008 Dec 1;26(34):5603-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18955445</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2009 Mar 10;27(8):1268-74</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19204207</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Neurosurgery. 1999 Dec;45(6):1442-53</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10598712</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2001 Jul 15;61(14):5349-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11454673</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2002 Jun 15;62(12):3335-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12067969</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2004 Jan 1;22(1):133-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14638850</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2004 Aug 15;22(16):3238-47</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15310767</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 1990 Jul;8(7):1277-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2358840</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7727-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8052651</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 1996 Nov 1;56(21):5079-86</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8895767</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Neurosurgery. 1997 Jan;40(1):141-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8971836</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Semin Surg Oncol. 1998 Jan-Feb;14(1):3-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9407626</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncol Res. 1997;9(11-12):581-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9563005</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Opin Oncol. 1999 May;11(3):162-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10328589</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2005 Apr 10;23(11):2544-55</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15753462</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>